We report the case of a patient with metastatic foot melanoma enrolled in a clinical trial of the anti‐RAS agent RMC‐6236 who developed chronic bilateral corneal epithelial defects and thinning, likely secondary to the systemic effects of targeted therapy. This case highlights the ocular surface toxicity associated with systemic anticancer therapies affecting rapidly dividing cells and the overall importance of multidisciplinary medical management of these systemic therapeutics.
Huynh et al. (2026) studied this question.